Our laboratory was founded 50 years ago, when Pierre Fabre developed the Cyclo 3 drug. Since then, a significant part of the turnover from our pharmaceutical activities has been spent on R&D for innovative treatments. We often work in partnership with public or private research laboratories to develop the drugs of tomorrow, mainly in the field of onco-hematology and dermatology.
Since Navelbine (vinorelbine) was first developed in partnership with the French National Centre for Scientific Research (CNRS) in the 1980s, Pierre Fabre has become recognized by oncologists all over the world. Today, oncology, be it in the areas of solid or liquid tumors, attracts the lion's share of Pierre Fabre Pharmaceutical investments.
In France, Pierre Fabre manages a significant range of prescription drugs, covering major treatment fields such as urology, gynecology, diabetes,cardiology, neuropsychitry, rheumatology and pneumo-allergology available to health care professionals and their patients, primarily in partnership with other pharmaceutical laboratories.